Related Experiment Video
Updated: Mar 3, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
A review of pomegranate in prostate cancer
C J Paller1, A Pantuck2, M A Carducci1
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Background:
Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials.
Methods:
Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC).
Results:
In the BCR patient population, early phase II trials of both pomegranate juice and extract showed significant lengthening of PSA doubling time (PSADT), and confirmed the safety of pomegranate products. While a placebo-controlled phase III trial determined that pomegranate extract did not significantly prolong PSADT in BCR patients, a preplanned subset analysis of patients with the manganese superoxide dismutase (MnSOD) AA genotype showed greater PSADT lengthening on the pomegranate extract arm. In the neoadjuvant population, a large trial demonstrated a significant increase in urolithin A and a non-significant reduction in 8-hydroxy-2-deoxyguanosine, a marker of oxidation in prostate cancer tissue, on the pomegranate arm vs the placebo arm. In addition, a randomized clinical trial of a polyphenol-rich multicomponent food supplement that included a 31.25% pomegranate extract found significant slowing of PSA increase in the food supplement arm vs placebo in men on active surveillance and those experiencing BCR.
Conclusions:
Pomegranate juice and extract are safe but did not significantly improve outcomes in BCR patients in a large placebo-controlled trial. However a subset of BCR patients with the MnSOD AA genotype appear to respond positively to the antioxidant effects of pomegranate treatment. Phase II trials of 100% pomegranate products in neoadjuvant patients and patients with mCRPC were negative. A multicomponent food supplement showed promising results in a phase II study in active surveillance and BCR patients.
Insights
Pomegranate products are safe for prostate cancer patients but did not significantly improve outcomes in most trials. However, a specific genotype showed positive response, and a food supplement demonstrated promise.
Area of Science:
- Oncology
- Nutritional Science
- Genetics
Background:
- Preclinical research indicated pomegranate's potential to inhibit prostate cancer growth.
- This led to clinical trials evaluating pomegranate products for slowing prostate cancer progression.
Purpose of the Study:
- To review preclinical data on pomegranate's effects on prostate cancer.
- To discuss the outcomes of clinical trials investigating pomegranate products in various prostate cancer patient groups.
Main Methods:
- Clinical trials included patients with biochemical recurrence (BCR), neoadjuvant prostate cancer, and metastatic castration-resistant prostate cancer (mCRPC).
- Studies assessed prostate-specific antigen doubling time (PSADT), oxidative stress markers, and safety of pomegranate interventions.
Main Results:
- Early trials showed pomegranate improved PSADT in BCR patients; however, a large trial did not confirm this overall.
- A subset of BCR patients with the manganese superoxide dismutase (MnSOD) AA genotype exhibited enhanced PSADT lengthening with pomegranate extract.
- A multicomponent food supplement containing pomegranate extract significantly slowed PSA increase in active surveillance and BCR patients.
Conclusions:
- Pomegranate juice and extract are safe but showed limited efficacy in large trials for BCR patients.
- A specific genetic profile (MnSOD AA genotype) may predict a positive response to pomegranate's antioxidant effects.
- A polyphenol-rich food supplement containing pomegranate extract demonstrated potential benefits for active surveillance and BCR patients.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Related Concept Videos
02:59Cancer Prevention
Some...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...